4-(2-bromo-4-fluorophenoxy)-7-(2-dimethylaminoethoxy)-6-methoxyquinazoline | 320366-05-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-(2-bromo-4-fluorophenoxy)-7-(2-dimethylaminoethoxy)-6-methoxyquinazoline
• 英文别名: 2-[4-(2-bromo-4-fluorophenoxy)-6-methoxyquinazolin-7-yl]oxy-N,N-dimethylethanamine
• CAS: 320366-05-0
• 化学式: C₁₉H₁₉BrFN₃O₃
• 分子量: 436.281
• InChiKey: SAMSZFGLMZNBDE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  27
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  56.7
• 氢给体数：
  0
• 氢受体数：
  7

文献信息

• QUINAZOLINE DERIVATIVES
  申请人：AstraZeneca UK Limited

  公开号：EP1218353B1

  公开（公告）日：2007-10-17
• USE OF QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS
  申请人：AstraZeneca AB

  公开号：EP1272185B1

  公开（公告）日：2005-07-27
• US6806274B1
  申请人：——

  公开号：US6806274B1

  公开（公告）日：2004-10-19
• [EN] THERAPY<br/>[FR] THERAPIE
  申请人：ASTRAZENECA AB

  公开号：WO2001066099A2

  公开（公告）日：2001-09-13

  The invention concerns the use of a quinazoline derivative of Formula (I) wherein Q1 includes a quinazoline ring optionally substituted with a group such as halogeno, trifluoromethyl and cyano, or a group of the formula: Q3-X1- wherein X1 includes a direct bond and O and Q3 includes aryl, aryl-(1-6C)alkyl, heterocyclyl and heterocyclyl-(1-6C)alkyl; each of R?2 and R3¿ is hydrogen or (1-6C)alkyl; Z includes O, S and NH; and Q2 includes aryl and aryl-(1-3C)alkyl or a pharmaceutically-acceptable salt thereof, in the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human.
• [EN] QUINAZOLINES WITH THERAPEUTIC USE<br/>[FR] QUINAZOLINES A USAGE THERAPEUTIQUE
  申请人：ASTRAZENECA AB

  公开号：WO2002002534A1

  公开（公告）日：2002-01-10

  The invention concerns the use of quinazoline derivatives of Formula (I) wherein Q1 includes a qinazoline ring optionally substituted with a group such as halogeno, trifluoromethyl and cyano, or a group of the formula: Q3-X1- wherein X1 includes a direct bond and O and Q3 includes aryl, aryl-(1-6C)alkyl, heterocyclyl and heterocyclyl-(1-6)alkyl; each of R?2 and R3¿ is hydrogen or (1-6C)alkyl; Z includes O, S and NH; and Q2 includes aryl and aryl-(1-3C)alkyl or a pharmaceutically-acceptable salt thereof; in the manufacture of a medicament for use as an anti-invasive agent in the containment and/or treatment of solid tumour disease.